Nasdaq Bpmc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq bpmc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Bpmc Today - Breaking & Trending Today

Blueprint Medicines (NASDAQ:BPMC) Price Target Increased to $76.00 by Analysts at Citigroup

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective hoisted by Citigroup from $65.00 to $76.00 in a report issued on Friday, Benzinga reports. They currently have a sell rating on the biotechnology company’s stock. Other equities research analysts have also recently issued reports about the stock. Stifel Nicolaus upped their price objective on […] ....

United States , Kate Haviland , Stifel Nicolaus , Christopherk Murray , Securities Exchange Commission , Financial Services Group Inc , Mirae Asset Global Investments Co , Associates Corp , Blueprint Medicines Corporation , Principal Financial Group Inc , Blueprint Medicines , Free Report , Moderate Buy , Medicines Trading Down , Get Free Report , Exchange Commission , Asset Global Investments , Financial Group , Services Group , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc , Boost Price Target , Citigroup Inc ,

Blueprint Medicines Co. (NASDAQ:BPMC) CFO Sells $1,050,000.00 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) CFO Michael Landsittel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $105.00, for a total value of $1,050,000.00. Following the transaction, the chief financial officer now owns 47,286 shares of […] ....

United States , Michael Landsittel , Blueprint Medicines Company Profile , Polar Capital Holdings Plc , Blueprint Medicines Co , Norges Bank , Goldman Sachs Group , Needham Company , Blueprint Medicines Corporation , Blueprint Medicines , Get Free Report , Medicines Stock Down , Capital Holdings Plc , Springs Capital Management , Partners Management , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc , Insider Trading , Nsider Trades ,

Blueprint Medicines (NASDAQ:BPMC) PT Raised to $135.00 at HC Wainwright

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $125.00 to $135.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential […] ....

United States , Piper Sandler , Christopherk Murray , Stifel Nicolaus , Jeffreyw Albers , Zurcher Kantonalbank Zurich Cantonalbank , Mirae Asset Global Investments Co , Securities Exchange Commission , York Mellon Corp , Brown Advisory Inc , Blueprint Medicines Corporation , Emerald Advisers , Blueprint Medicines , Get Free Report , Director Jeffrey , Exchange Commission , New York Mellon Corp , Kantonalbank Zurich Cantonalbank , Asset Global Investments , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc , Boost Price Target , Hc Wainwright ,

Blueprint Medicines (NASDAQ:BPMC) Given New $125.00 Price Target at JMP Securities

Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective increased by JMP Securities from $114.00 to $125.00 in a report issued on Friday morning, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock. BPMC has been the subject of a number of other research reports. Barclays lifted their target […] ....

United States , Jeffreyw Albers , Christopherk Murray , Piper Sandler , Stifel Nicolaus , China Universal Asset Management Co , Securities Exchange Commission , Blueprint Medicines Corporation , Rafferty Asset Management , Needham Company , Blueprint Medicines Company Profile , American Century Companies Inc , Blueprint Medicines , Free Report , Get Free Report , Director Jeffrey , Exchange Commission , Asset Management , Century Companies , Universal Asset Management , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc , Boost Price Target , Jmp Securities ,

Blueprint Medicines (NASDAQ:BPMC) PT Raised to $75.00

Blueprint Medicines (NASDAQ:BPMC – Get Free Report) had its price target boosted by equities research analysts at Barclays from $70.00 to $75.00 in a report released on Friday, Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Barclays‘s price target would suggest a potential downside of 30.23% from the […] ....

United States , Jeffreyw Albers , Christopherk Murray , Associates Corp , Blueprint Medicines Corporation , Financial Services Group Inc , Blueprint Medicines Company Profile , Needham Company , Mirae Asset Global Investments Co , Principal Financial Group Inc , Blueprint Medicines , Get Free Report , Director Jeffrey , Asset Global Investments , Financial Group , Services Group , Medicines Corporation , Blueprint Medicines Daily , Nasdaq Bpmc , Boost Price Target , Barclays Plc ,